Literature DB >> 30061265

CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy.

Valentina Ciaravino1, Nicolò Cardobi2, Riccardo DE Robertis2, Paola Capelli3, Davide Melisi4, Francesca Simionato4, Giovanni Marchegiani5, Roberto Salvia5, Mirko D'Onofrio6.   

Abstract

BACKGROUND/AIM: Re-staging of ductal adenocarcinoma using computed tomography (CT) scan can be problematic so new imaging techniques and evaluation parameters are required. The aim of the study was to evaluate the added value of CT texture analysis in estimation of tissue changes in ductal adenocarcinoma downsized and resected after chemotherapy.
MATERIALS AND METHODS: Patients with ductal adenocarcinoma downstaged after neoadjuvant treatment, and resected, were included. A pre- and post-treatment CT was obtained. In comparison, patients with disease progression were included for texture analysis evaluation at CT pre- and post-treatment. CT texture analysis results were compared.
RESULTS: A total of 17 patients affected by un-resectable or borderline ductal adenocarcinoma reached the resectable stage after treatment. The comparison between Kurtosis pre- and Kurtosis post-treatment showed a statistically significant difference. On the contrary, in the comparison group composed of 14 patients with disease progression there was no statistical difference regarding this parameter.
CONCLUSION: This evaluation may represent an added value in tumor tissue changes judgment and can be extremely useful to diagnose downstaging in those cases with no evident downsizing after chemotherapy. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Texture analysis; downstaged adenocarcinoma; neoadjuvant treatment; pancreatic cancer; pancreatic ductal adenocarcinoma

Mesh:

Year:  2018        PMID: 30061265     DOI: 10.21873/anticanres.12803

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

Review 1.  CT and MRI of pancreatic tumors: an update in the era of radiomics.

Authors:  Marion Bartoli; Maxime Barat; Anthony Dohan; Sébastien Gaujoux; Romain Coriat; Christine Hoeffel; Christophe Cassinotto; Guillaume Chassagnon; Philippe Soyer
Journal:  Jpn J Radiol       Date:  2020-10-21       Impact factor: 2.374

2.  Retrospective Analysis of the Value of Enhanced CT Radiomics Analysis in the Differential Diagnosis Between Pancreatic Cancer and Chronic Pancreatitis.

Authors:  Xi Ma; Yu-Rui Wang; Li-Yong Zhuo; Xiao-Ping Yin; Jia-Liang Ren; Cai-Ying Li; Li-Hong Xing; Tong-Tong Zheng
Journal:  Int J Gen Med       Date:  2022-01-06

3.  Liver metastases in pancreatic ductal adenocarcinoma: a predictive model based on CT texture analysis.

Authors:  Riccardo De Robertis; Luca Geraci; Luisa Tomaiuolo; Luca Bortoli; Alessandro Beleù; Giuseppe Malleo; Mirko D'Onofrio
Journal:  Radiol Med       Date:  2022-09-04       Impact factor: 6.313

Review 4.  Pancreas image mining: a systematic review of radiomics.

Authors:  Bassam M Abunahel; Beau Pontre; Haribalan Kumar; Maxim S Petrov
Journal:  Eur Radiol       Date:  2020-11-05       Impact factor: 5.315

Review 5.  Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment.

Authors:  Nina J Wesdorp; Tessa Hellingman; Elise P Jansma; Jan-Hein T M van Waesberghe; Ronald Boellaard; Cornelis J A Punt; Joost Huiskens; Geert Kazemier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-16       Impact factor: 9.236

Review 6.  Update on quantitative radiomics of pancreatic tumors.

Authors:  Mayur Virarkar; Vincenzo K Wong; Ajaykumar C Morani; Eric P Tamm; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2021-07-22

7.  A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.

Authors:  Francesca Simionato; Camilla Zecchetto; Valeria Merz; Alessandro Cavaliere; Simona Casalino; Marina Gaule; Mirko D'Onofrio; Giuseppe Malleo; Luca Landoni; Alessandro Esposito; Giovanni Marchegiani; Luca Casetti; Massimiliano Tuveri; Salvatore Paiella; Filippo Scopelliti; Alessandro Giardino; Isabella Frigerio; Paolo Regi; Paola Capelli; Stefano Gobbo; Armando Gabbrielli; Laura Bernardoni; Vita Fedele; Irene Rossi; Cristiana Piazzola; Serena Giacomazzi; Martina Pasquato; Morena Gianfortone; Stefano Milleri; Michele Milella; Giovanni Butturini; Roberto Salvia; Claudio Bassi; Davide Melisi
Journal:  Ther Adv Med Oncol       Date:  2020-09-04       Impact factor: 8.168

Review 8.  Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine.

Authors:  Federica Vernuccio; Carlo Messina; Valeria Merz; Roberto Cannella; Massimo Midiri
Journal:  Diagnostics (Basel)       Date:  2021-11-22

Review 9.  Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.

Authors:  Yun Zhang; Zi-Xing Huang; Bin Song
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

10.  CT radiomic models to distinguish COVID-19 pneumonia from other interstitial pneumonias.

Authors:  Nicolò Cardobi; Giulio Benetti; Giuseppe Cardano; Cinzia Arena; Claudio Micheletto; Carlo Cavedon; Stefania Montemezzi
Journal:  Radiol Med       Date:  2021-05-27       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.